Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) reached a new 52-week high on Friday . The stock traded as high as GBX 9 and last traded at GBX 9, with a volume of 339270 shares trading hands. The stock had previously closed at GBX 8.50.
Allergy Therapeutics Stock Up 1.2%
The stock’s fifty day simple moving average is GBX 8.26 and its two-hundred day simple moving average is GBX 7.87. The company has a debt-to-equity ratio of 835.48, a current ratio of 1.63 and a quick ratio of 1.48. The company has a market capitalization of £528.16 million, a price-to-earnings ratio of -11.94, a PEG ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Featured Stories
- Five stocks we like better than Allergy Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Rigetti’s Q3 Miss Reveals Quantum Funding and Timing Pressures
- How to Effectively Use the MarketBeat Ratings Screener
- Monolithic Power Surges in 2025—Time to Buy or Hold?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Tesla Has Been Trapped in a 10% Range for Months—What’s Going On?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
